IGF2: Insulin-like growth factor 2
The insulin-like growth factors possess growth-promoting activity.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on IGF2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 2
| Dusigitumab | Phase 2 | MedImmune LLC | Antibody | InhibitorInsulin-like growth factor II inhibitor | 0 |
| Xentuzumab | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Antibody | InhibitorInsulin-like growth factor II inhibitor | 0 |
- Silver-Russell syndrome due to a point mutation0.72
- Silver-Russell syndrome0.69
- Beckwith-Wiedemann syndrome0.59
- Diabetes mellitus, permanent neonatal 40.48
- Maturity-onset diabetes of the young type 100.47
- Hyperproinsulinemia0.45
- Permanent neonatal diabetes mellitus0.42
- Hereditary disease0.41
- Isolated hemihyperplasia0.38
- Beckwith-Wiedemann syndrome due to imprinting defect of 11p150.37
- Diabetes mellitus0.36
- Colorectal cancer0.35
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712957, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01344, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets